Over a thousand women are taking legal action against pharmaceutical giant Pfizer, alleging that the contraceptive injection Depo-Provera led to the development of brain tumors. Specifically, the cases focus on non-cancerous meningioma brain tumors that have occurred in some users after prolonged use of the drug. According to PIX11 News, Miller & Zois, a law firm representing some of these women, cites studies that suggest a connection between the drug and the formation of meningiomas.
In a legal maneuver, the number of lawsuits has swelled to more than 1,300 and are being consolidated in the federal multi-district litigation process. These cases are said to possibly payout individual settlements starting from $275,000 to over $1.5 million, with total claim values potentially reaching to several billion dollars. A hearing in Pensacola, Florida, is set to debate whether Pfizer can rely on a pre-emption defense to circumvent liability—a strategy commonly used in drug litigation that posits a company cannot be sued if the FDA approved the drug's marketing as it was. However, plaintiffs argue that Pfizer's request to the FDA was too broad and therefore mischaracterized the risks of Depo-Provera. This information was reported by The Guardian.
Depo-Provera, or medroxyprogesterone acetate, delivers a dose of hormones through an injection every three months to prevent pregnancy and manage menstruation-related conditions, like anemia and endometriosis. Despite its FDA approval for over 30 years, new research has begin to formally outline the potential risks, including a British Medical Journal study highlighting a 5.6-fold increased risk of developing brain tumors with extended use of the drug.
As the number of lawsuits expect to significantly grow, ranging between 5,000 and 10,000, these legal proceedings may mark a significant turning point in the accountability of pharmaceutical companies for possible side effects of long-term drug use. Virginia Buchanan of Levin Papantonio, in a statement obtained by The Guardian, said, "Pfizer is attempting to avoid accountability by invoking a pre-emption defence, yet there are serious questions about whether it ever provided the FDA with the full picture." Berger Montague, another law firm, is also investigating Pfizer for possible shareholder legal action due to the company's handling and marketing of Depo-Provera.
Pfizer has not commented on the lawsuits but maintains that Depo-Provera is safe and effective for patients. The company has updated warning labels in Canada and Europe to include information about possible risks linked to long-term progestogen use. Legal and medical experts are monitoring the upcoming court cases to understand their potential impact on women’s health and pharmaceutical regulations.
